Background*

Dr. Samuel L. Barker, also known as Sam, Ph.D. was Operating Partner at Behrman Capital. Dr. Barker served at Bristol-Myers Squibb for over 35 years in research and development, manufacturing, business development, sales and marketing, and general management. After the merger of Bristol-Myers and Squibb in 1989, he assumed the position of Vice President of Asia-Pacific for the Pharmaceutical Group. Since 1991, he served as the President of Intercontinental at Bristol-Myers ... Squibb Company. From 1992 to retiring in May 1999, he served as the President of United States Pharmaceuticals Group. He co-founded Clearview Projects, and served as its President and Chief Executive Officer from 2003 to 2004.He has been the Chairman of the Board of Lexicon Genetics, Inc. since March 2005 and serves on the Board of Directors of UCB, United States. He has been a Director of Lexicon Genetics Inc. since March 2000. He has been an Independent Director of Cadence Pharmaceuticals, Inc. since 2008. He served as the Chairman at Lexicon Pharmaceuticals, Inc. since March 21, 2005 until 2012 and has been its Director since March 2000. He serves as a Trustee of University of the Sciences In Philadelphia. He has been a Director of Cyclacel Pharmaceuticals, Inc. since September 1, 2014. He served as a Director of Atherogenics Inc., since July 2006. He is a Member of the Board of Trustees at the Cancer Institute of New Jersey. He holds a Ph.D. in Bionucleonics and Radiobiology from the School of Pharmacy at Purdue University and also graduated from the same university. Dr. Barker received a B.S. in Biology from Henderson State College and holds MS in Health Physics from the University of Arkansas.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.